πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 1,015 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11596696

Combination therapy with an anti-CD25 antibody-drug conjugate

ADC THERAPEUTICS SA Β· Granted Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11578127

Anti-Fc epsilon-R1 alpha (FcΞ΅R1Ξ±) antibodies, bispecific antigen-binding molecules that bi

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Feb 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11572372

Anti-HBVtetrahydroisoxazolo[4,3-c]pyridine compounds

Medshine Discovery Inc. Β· Granted Tue Feb 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11564937

Nucleoporins as drug targets for anti-proliferative therapeutics

SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE Β· Granted Tue Jan 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11566076

Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancers

Five Prime Therapeutics, Inc. Β· Granted Tue Jan 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11559583

Anti-CSF1R antibody and agonistic anti-CD40 antibody combination therapy for cancer

Five Prime Therapeutics, Inc. Β· Granted Tue Jan 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11559576

Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jan 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11548940

Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract u

Rani Therapeutics, LLC Β· Granted Tue Jan 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11548947

Bispecific anti-PSMA X anti-CD28 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jan 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11548932

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jan 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11541070

Administration of an anti-activin-A compound to a subject

Atara Biotherapeutics, Inc. Β· Granted Tue Jan 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11542312

IL-2 superagonists in combination with anti-PD-1 antibodies

Medicenna Therapeutics Inc. Β· Granted Tue Jan 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11542317

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jan 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11542326

Anti-IL-25 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jan 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11534430

Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and an

Lutonix, Inc. Β· Granted Tue Dec 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11529312

Francisella lipids as broad anti-inflammatory therapeutics and associated methods of use

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Dec 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11524017

Method of using substrates of AKR1B1/AKR1B10 as anti-cancer drugs

Beijing Normal University Hong Kong Baptist University United International College Β· Granted Tue Dec 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11525001

Anti-CD8 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Dec 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11524053

Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents

The Regents of the University of California Β· Granted Tue Dec 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11518818

Therapeutic anti-IgE antibodies and methods and compositions thereof

The Regents of the University of California Β· Granted Tue Dec 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11519020

Methods of associating genetic variants with a clinical outcome in patients suffering from

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Dec 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11517606

Composition having anti-glycation effect and application thereof

INFINITUS (CHINA) COMPANY LTD. Β· Granted Tue Dec 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11511001

Radiolabeled anti-LAG3 antibodies for immuno-PET imaging

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Nov 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11505593

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Nov 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted